Do Today’s Results Make GlaxoSmithKline plc A Contrarian Buy?

Roland Head explains why after a disappointing 2015, GlaxoSmithKline plc (LON:GSK) may now be poised to deliver real growth.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in GlaxoSmithKline (LSE: GSK) have risen modestly so far this afternoon, despite the company reporting a 21% fall in core earnings for 2015.

City investors were pleased because Glaxo’s full-year results, which were published at noon on Wednesday, were exactly in line with forecasts. Revenue of £23.9bn was up 4% on the year, while earnings per share of 75.7p matched up with forecasts for earnings of 75.9p per share.

Although there were declines in various areas, these appear to be stabilising and were as expected. The whole picture is one of a company that should be able to fulfil its promise of returning to growth in 2016.

Should you invest £1,000 in British American Tobacco right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if British American Tobacco made the list?

See the 6 stocks

Shares in Glaxo have trended lower since mid-2013. The firm has had to cope with a sharp decline in sales of key respiratory products and a major restructuring. Glaxo stock is worth around 15% less than when it peaked in May 2013, but the firm has been able to protect its dividend.

Dividend strength?

Today, Glaxo confirmed an ordinary dividend of 80p for 2015, plus a special dividend of 20p. This will be paid alongside the final dividend in April and will mean that shareholders have received a trailing yield of 6.9% this year. That’s a decent compensation for the firm’s lacklustre share price performance, in my view.

Glaxo confirmed today that it expects to pay a dividend of 80p in both 2016 and 2017. While growth isn’t on the cards, I can live with a flat payout for a couple of years if the firm’s turnaround continues to plan.

Today’s figures suggest that the underlying performance of the business remains strong. Glaxo’s core operating profit margin was 23.9%. The profits from the sale of the Oncology business were used to reduce net debt from £14.4bn to £10.7bn. This should cut finance costs going forward and strengthens the firm’s balance sheet.

New products = new sales

Although Glaxo has suffered from falling sales of its ex-patent product Advair, the group does have a pipeline of new products which are now starting to feed through to sales.

£2bn of new product sales were reported for last year, driven mainly by Glaxo’s HIV business and its respiratory division. New product sales are now expected to hit the group’s target level of £6bn in 2018, two years ahead of the original 2020 target date.

Outlook improving

In May 2015, Glaxo told investors that it hopes to achieve mid-to-high single digit annual growth in core earnings per share between 2016 and 2020, excluding exchange rate movements.

Today’s results give me confidence that this target is reasonable. Indeed, the firm may manage to beat its own targets. In its guidance for 2016, Glaxo said that it hopes to achieve double-digit earnings per share growth, on a constant exchange rate basis.

This ties in with the latest analysts’ forecasts, which suggest that Glaxo’s core earnings per share could rise by 11% to 84.4p in 2016. This puts the firm’s stock on a forecast P/E of 16.9 with a prospective yield of 5.5%.

This looks attractive to me, and I recently added more Glaxo shares to my portfolio. I rate the stock as a strong long-term income buy.

5 stocks for trying to build wealth after 50

The cost of living crisis shows no signs of slowing… the conflict in the Middle East and Ukraine shows no sign of resolution, while the global economy could be teetering on the brink of recession.

Whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times. Yet despite the stock market’s recent gains, we think many shares still trade at a discount to their true value.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. We believe these stocks could be a great fit for any well-diversified portfolio with the goal of building wealth in your 50’s.

Claim your free copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

many happy international football fans watching tv
Investing Articles

Is ITV the best FTSE bargain stock about today?

ITV has a streaming platform and the stock looks great value. But is this enough to justify investing in the…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

Lloyds shares recently hit a 52-week high — is it too late to consider buying?

Lloyds shares have been on a roll in the past year. But is there still value for investors, or has…

Read more »

Two business people sitting at cafe working on new project using laptop. Young businesswoman taking notes and businessman working on laptop computer.
Investing Articles

Want to start buying shares with under £500? It’s possible – here’s how!

The stock market isn't just for millionaires. This writer thinks someone with just a few hundred pounds to spare could…

Read more »

Tesla building with tesla logo and two teslas in front
Investing Articles

Here’s how much £150 invested in Tesla stock 10 years ago is worth now!

Christopher Ruane looks back on how Tesla stock has performed over the past decade and sets out his investing plan…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

5 steps to start earning passive income this summer, for £5 a day

With a fiver a day, this writer reckons it's possible for someone to set up passive income streams in the…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

£20,000 invested in this 5-stock ISA could generate a £1,400 second income

Our writer highlighs five dividend shares from the FTSE 100 blue-chip index that could form the basis of an attractive…

Read more »

Road trip. Father and son travelling together by car
Investing Articles

£10,000 invested in Tesla shares a year ago is now worth this much

Tesla shares have been on one of the scariest boom-and-bust rides of the past 12 months. Here's what the result…

Read more »

Three generation family are playing football together in a field. There are two boys, their father and their grandfather.
Investing Articles

£10,000 invested in Manchester United shares in an ISA 1 year ago is now worth… 

Our writer digs into an iconic Premier League football club to see whether it shares might be a good fit…

Read more »